Clinical Trial

Short-course Radiotherapy Followed by Fruquintinib Plus Adebrelimab and CAPOX in the Full Course Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Multicenter, Single-arm, Open-label Study

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated March 18, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
To investigate the efficacy and safety of short-course radiotherapy sequential fruquintinib in combination with adebrelimab and CAPOX (full course neoadjuvant therapy) in patients with locally advanced rectal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-22.
Trial Details
NCT Number NCT06234007
Lead Sponsor Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborators: Renmin Hospital of Wuhan University
Conditions Locally Advanced Rectal Cancer
Enrollment 45 participants
Start Date 2023-12-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-03-18